Daewoong Pharmaceutical Co. LTD.: Dyslipidemias trials
The registry lists 13 Dyslipidemias studies with Daewoong Pharmaceutical Co. LTD. as lead sponsor. 2 are open to participants now and 0 have results posted.
Phase 3 4Phase 4 1No phase 8(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Efficacy and Safety of Baroezet Tablet in Korean Patients With Dyslipidemia: A Prospective Observational StudyNot yet recruitingNCT07515560
- Evaluation of Enavogliflozin's Efficacy and Safety in Type II Diabetes With Hypertension or DyslipidemiaRecruitingNCT06647888
- To Investigate Blood Lipid Changes and Safety After Litorvazet® Tablets in Dyslipidemia PatientsCompletedNCT06866509
- A Study to Evaluate the Efficacy and Safety of CREZET TabletActive, not recruitingNCT05889143
- Reduction Efficacy of OLOMAX for Blood Pressure and Low-density Lipoprotein Cholesterol in Hypertensive Patients With DyslipidemiaActive, not recruitingNCT05660135
- Evaluation of Dyslipidemia Management After Statin and Ezetimibe Complex TreatmentActive, not recruitingNCT05614765
- Observational Study to Evaluate the Therapeutic Effectiveness and Safety of Olomax TabCompletedNCT05184179
- Evaluate the Efficacy and Safety of DWJ1506 and DWJ1507Status unknownNCT04772443Phase 3
- Clinical Trail to Evaluate the Efficacy and Safety of DWJ1451Status unknownNCT04161001Phase 3
- Clinical Trial to Evaluate the Efficacy and Safety of OLOMAX TabCompletedNCT04120753Phase 4
- Observational Study to Investigate the Effectiveness and Safety of Olostar Tab in Patients With Essential Hypertension and DyslipidemiaStatus unknownNCT03009721
- Metformin/Atorvastatin Combination Therapy in Subjects With Type II Diabetes and Dyslipidemia (Phase 3)CompletedNCT02947620Phase 3
- Clinical Study for Patients With Hypertension Associated With DyslipidemiaCompletedNCT01764295Phase 3